- Home
- MKL vs BIIB Comparison
MKL vs BIIB Comparison
Compare MKL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKL
- BIIB
- Stock Information
- Founded
- MKL 1930
- BIIB 1978
- Country
- MKL United States
- BIIB United States
- Employees
- MKL N/A
- BIIB N/A
- Industry
- MKL Property-Casualty Insurers
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- MKL Finance
- BIIB Health Care
- Exchange
- MKL Nasdaq
- BIIB Nasdaq
- Market Cap
- MKL 24.0B
- BIIB 19.9B
- IPO Year
- MKL 1986
- BIIB 1991
- Fundamental
- Price
- MKL $1,768.53
- BIIB $118.61
- Analyst Decision
- MKL Hold
- BIIB Buy
- Analyst Count
- MKL 5
- BIIB 28
- Target Price
- MKL $1,702.20
- BIIB $220.29
- AVG Volume (30 Days)
- MKL 62.2K
- BIIB 1.9M
- Earning Date
- MKL 04-30-2025
- BIIB 05-01-2025
- Dividend Yield
- MKL N/A
- BIIB N/A
- EPS Growth
- MKL 35.61
- BIIB 40.28
- EPS
- MKL 199.32
- BIIB 11.18
- Revenue
- MKL $16,620,762,999.00
- BIIB $9,675,900,000.00
- Revenue This Year
- MKL N/A
- BIIB N/A
- Revenue Next Year
- MKL $4.64
- BIIB N/A
- P/E Ratio
- MKL $8.87
- BIIB $10.61
- Revenue Growth
- MKL 5.17
- BIIB N/A
- 52 Week Low
- MKL $1,417.65
- BIIB $110.04
- 52 Week High
- MKL $2,063.68
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- MKL 44.23
- BIIB 38.12
- Support Level
- MKL $1,751.57
- BIIB $110.04
- Resistance Level
- MKL $1,800.00
- BIIB $119.99
- Average True Range (ATR)
- MKL 61.45
- BIIB 5.59
- MACD
- MKL -0.98
- BIIB -0.68
- Stochastic Oscillator
- MKL 56.28
- BIIB 30.65
About MKL Markel Group Inc.
Markel's primary business is property and casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The acquisition of Alterra in 2013 added substantial reinsurance operations, which now account for a little less than 15% of premiums. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.